Metabolic syndrome and bladder carcinoma ‒ A cross-sectional study

Background and Objective: Urinary bladder carcinoma is one of the most common carcinomas of the genitourinary tract. Smoking and male sex being an established etiological factor for bladder carcinoma, the rising incidence is seen in nonsmokers as well as in females suggesting other probable etiologi...

Full description

Saved in:
Bibliographic Details
Main Authors: Soumya Mondal, Eeshansh Khare, Dilip Kumar Pal
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-05-01
Series:Annals of Medical Science and Research
Subjects:
Online Access:https://journals.lww.com/10.4103/amsr.amsr_8_22
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849396682652909568
author Soumya Mondal
Eeshansh Khare
Dilip Kumar Pal
author_facet Soumya Mondal
Eeshansh Khare
Dilip Kumar Pal
author_sort Soumya Mondal
collection DOAJ
description Background and Objective: Urinary bladder carcinoma is one of the most common carcinomas of the genitourinary tract. Smoking and male sex being an established etiological factor for bladder carcinoma, the rising incidence is seen in nonsmokers as well as in females suggesting other probable etiologies such as metabolic syndrome. Our intention was to know the association between metabolic syndrome and the risk of urinary bladder carcinoma and its histopathological grading. Materials and Methods: A retrospective cross-sectional study of 201 patients was performed after ethics clearance in a tertiary care hospital in India, between June 1, 2017, and May 31, 2019. The data of patients of urothelial carcinoma bladder were divided into two groups based on the presence or absence of metabolic syndrome and its associated variables for comparison and evaluation. Results: Of the total 201 patients, 15 patients had metabolic syndrome. In metabolic syndrome patients, ten patients had high-grade tumors and five patients had low-grade tumors. Moreover, in metabolic syndrome negative patients, 145 were of low grade and 41 were of high grade. Body mass index >30, triglyceride levels >150 mg/dL, and high-density lipoprotein level <40 mg/dL were mostly present in patients of metabolic syndrome, and its association was statistically significant. Interpretation and Conclusion: Metabolic syndrome is associated with high-grade urothelial carcinoma of the bladder. Hence, patients with the risk factors for metabolic syndrome and without urinary symptoms should be properly screened for bladder cancer as there may be bladder carcinoma in the early stage and its timely diagnosis and intervention can prolong the survival of these patients.
format Article
id doaj-art-aeb4dbc1bd934cb29fa2b3f4e57b0336
institution Kabale University
issn 2949-785X
language English
publishDate 2022-05-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Annals of Medical Science and Research
spelling doaj-art-aeb4dbc1bd934cb29fa2b3f4e57b03362025-08-20T03:39:15ZengWolters Kluwer Medknow PublicationsAnnals of Medical Science and Research2949-785X2022-05-0112697310.4103/amsr.amsr_8_22Metabolic syndrome and bladder carcinoma ‒ A cross-sectional studySoumya MondalEeshansh KhareDilip Kumar PalBackground and Objective: Urinary bladder carcinoma is one of the most common carcinomas of the genitourinary tract. Smoking and male sex being an established etiological factor for bladder carcinoma, the rising incidence is seen in nonsmokers as well as in females suggesting other probable etiologies such as metabolic syndrome. Our intention was to know the association between metabolic syndrome and the risk of urinary bladder carcinoma and its histopathological grading. Materials and Methods: A retrospective cross-sectional study of 201 patients was performed after ethics clearance in a tertiary care hospital in India, between June 1, 2017, and May 31, 2019. The data of patients of urothelial carcinoma bladder were divided into two groups based on the presence or absence of metabolic syndrome and its associated variables for comparison and evaluation. Results: Of the total 201 patients, 15 patients had metabolic syndrome. In metabolic syndrome patients, ten patients had high-grade tumors and five patients had low-grade tumors. Moreover, in metabolic syndrome negative patients, 145 were of low grade and 41 were of high grade. Body mass index >30, triglyceride levels >150 mg/dL, and high-density lipoprotein level <40 mg/dL were mostly present in patients of metabolic syndrome, and its association was statistically significant. Interpretation and Conclusion: Metabolic syndrome is associated with high-grade urothelial carcinoma of the bladder. Hence, patients with the risk factors for metabolic syndrome and without urinary symptoms should be properly screened for bladder cancer as there may be bladder carcinoma in the early stage and its timely diagnosis and intervention can prolong the survival of these patients.https://journals.lww.com/10.4103/amsr.amsr_8_22metabolic syndromeobesityurothelial carcinoma
spellingShingle Soumya Mondal
Eeshansh Khare
Dilip Kumar Pal
Metabolic syndrome and bladder carcinoma ‒ A cross-sectional study
Annals of Medical Science and Research
metabolic syndrome
obesity
urothelial carcinoma
title Metabolic syndrome and bladder carcinoma ‒ A cross-sectional study
title_full Metabolic syndrome and bladder carcinoma ‒ A cross-sectional study
title_fullStr Metabolic syndrome and bladder carcinoma ‒ A cross-sectional study
title_full_unstemmed Metabolic syndrome and bladder carcinoma ‒ A cross-sectional study
title_short Metabolic syndrome and bladder carcinoma ‒ A cross-sectional study
title_sort metabolic syndrome and bladder carcinoma a cross sectional study
topic metabolic syndrome
obesity
urothelial carcinoma
url https://journals.lww.com/10.4103/amsr.amsr_8_22
work_keys_str_mv AT soumyamondal metabolicsyndromeandbladdercarcinomaacrosssectionalstudy
AT eeshanshkhare metabolicsyndromeandbladdercarcinomaacrosssectionalstudy
AT dilipkumarpal metabolicsyndromeandbladdercarcinomaacrosssectionalstudy